Lipigon Pharmaceuticals is a leading brand specializing in lipid biology. They combine cutting-edge lipid research with expertise in drug development to create safe and effective treatments for lipid-related diseases. With over 50 years of lipid research at Umeå University as a foundation, Lipigon aims to be a key player in the field and a trusted partner for big pharma.

Their focus is on orphan drugs and niche indications, which can later be developed for broader conditions such as diabetes and cardiovascular disease. Lipigon's drug development revolves around four projects, all of which have the potential to target wider indications related to blood lipids, their regulation, and significance. Their pipeline comprises four active projects: Lipisense, an RNA drug targeting elevated triglycerides; an RNA drug project for acute respiratory distress syndrome (ARDS); a gene therapy project for the rare disease lipodystrophy in collaboration with Combigene AB; and a small molecule project for dyslipidemia (general lipid disorders) in partnership with HitGen, Inc.

Excitingly, Lipigon initiated clinical trials for Lipisense in May 2022, marking a significant milestone for the brand. To learn more about the progress and next steps, check out their interview with Stefan Pierrou, PhD, M. Sc., project manager for drug development at Lipigon.

Stay updated with Lipigon through their news section, where they share press releases and company updates like the recent publication of their interim report for January-June 2023 and the company's CEO, Stefan K. Nilsson, increasing his stake in the company. Lipigon Pharmaceuticals is dedicated to transforming the treatment landscape for lipid-related diseases and bringing hope to patients who currently lack satisfactory treatment options.

Contact them or explore their website to learn more about their revolutionary work in lipid research and drug development